Pre-diagnostic plasma urate and the risk of amyotrophic lateral sclerosis

  • Éilis J. O’Reilly
  • , Kjetil Bjornevik
  • , Michael A. Schwarzschild
  • , Marjorie L. McCullough
  • , Laurence N. Kolonel
  • , Loic Le Marchand
  • , Joann E. Manson
  • , Alberto Ascherio

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: To prospectively examine for the first time the association between plasma urate levels measured in healthy participants and future amyotrophic lateral sclerosis (ALS) risk. Methods: A pooled case-control study nested in five US prospective cohorts comprising 319,617 participants who provided blood, of which 275 had ALS during follow-up. Pre-diagnostic plasma urate was determined for all participants using a clinical colorimetric enzyme assay. Gender-specific multivariable-adjusted rate ratios (RR) of ALS incidence or death estimated by conditional logistic regression and pooled using inverse-variance weighting. Results: In age- and matching factor-adjusted analyses, a 1 mg/dL increase in urate concentration was associated with RR = 0.88 (95% CI: [0.78, 0.997] p = 0.044). After adjustment for BMI, a strong predictor of ALS and urate levels, and other potential covariates, the RR = 0.89 (95% CI: [0.78, 1.02]; p = 0.08 for 1mg/dL increase in urate). Conclusion: Elevation of plasma urate was modestly inversely associated with the risk of ALS and warrants further study for a potential role in this disease.

Original languageEnglish
Pages (from-to)194-200
Number of pages7
JournalAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration
Volume19
Issue number3-4
DOIs
Publication statusPublished - 3 Apr 2018

Keywords

  • biomarkers
  • Epidemiology
  • risk

Fingerprint

Dive into the research topics of 'Pre-diagnostic plasma urate and the risk of amyotrophic lateral sclerosis'. Together they form a unique fingerprint.

Cite this